tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Chad Messer, 171 are a BUY (97.16%), 4 are a HOLD (2.27%), 1 are a SELL (0.57%).
Analyst Chad Messer, currently employed at LAKE STREET, carries an average stock price target met ratio of 42.32% that have a potential upside of 54.19% achieved within 304 days. Previously, Chad Messer worked at NEEDHAM.
Chad Messer’s has documented 346 price targets and ratings displayed on 34 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on IMNM, Immunome at 16-Dec-2025.
Analyst best performing recommendations are on ARQL (ARQULE).
The best stock recommendation documented was for ESPR (ESPERION THERAPEUTICS) at 3/6/2015. The price target of $104 was fulfilled within 12 days with a profit of $38.72 (59.31%) receiving and performance score of 49.43.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 25-Apr-2026
$50
$18.2 (57.23%)
$46
12 days ago
(21-Sep-2026)
1/3 (33.33%)
$16.05 (47.28%)
73
Hold Since 01-Dec-2022
$34
$2.2 (6.92%)
$31
1 months 26 days ago
(07-Aug-2026)
9/10 (90%)
$1.73 (5.36%)
123
Buy Since 05-Mar-2026
$52
$20.2 (63.52%)
$46
2 months 2 days ago
(31-Jul-2026)
1/3 (33.33%)
$21.98 (73.22%)
215
Buy Since 05-Jan-2024
$39
$7.2 (22.64%)
$41
2 months 2 days ago
(31-Jul-2026)
10/12 (83.33%)
$8.98 (29.91%)
95
Buy Since 24-Feb-2025
$55
$23.2 (72.96%)
$52
2 months 3 days ago
(30-Jul-2026)
0/12 (0%)
$22.25 (67.94%)
What Year was the first public recommendation made by Chad Messer?
